In a phase 1a/b trial of 83 people (18 healthy volunteers randomised to imdusiran or placebo; 65 with chronic hepatitis B given open-label single or repeat doses), no one stopped imdusiran for adverse events, there were no deaths and part 3 events were all grade 1.
RCTn = 83
Yuen et al. The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial